Heart Failure Pharmacotherapy An Update
|
|
- Clemence Lane
- 6 years ago
- Views:
Transcription
1 Heart Failure Pharmacotherapy An Update Kenneth Mishler, PharmD, MBA Objectives Review the epidemiology of heart failure (HF) Review evidence based guidelines for the use of mediations used to treat HF Review new therapies Review evidence based guidelines to reduce HF related emergency department visits, hospitalizations and rehospitalizations Heart Failure Facts 5.7 million adults in the US are living with HF One in nine deaths in 2009 included heart failure as a contributing cause About half of people who develop heart failure die within 5 years of diagnosis Heart failure costs the nation an estimated $30.7 billion each year. This total includes the cost of health care services, medications and missed days of work. 1
2 HF Deaths by Geography Characteristics of HF Hospitalizations Over 1 million hospitalizations occur each year in the US Over 500,000 emergency department visits annually Heart failure accounts for 25% of all cardiovascular related admissions. 20% are for new onset HF 80% represent readmissions Approximately 20% of all HF discharges are readmitted within the first 30 days. The five most common reasons for readmissions are 1) exacerbation of HF, 2) renal disease, 3) pneumonia, 4) cardiac arrhythmia, 5) sepsis. Desai AS. The three phase terrain of heart failure readmissions. Cir Heart Fail. 2012;5: Centers for Medicare & Medicaid Services. Readmissions Reduction Program. Available at: Fee for Service Payment/AcuteinpatientPPS/Readmissions Reduction Program.html. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics 2015 update: a report from the American Heart Association. Circulation. 2015;131:e Classification of Heart Failure 2
3 Definition of Heart Failure Citations for HF Guidelines 2013 ACCF / AHA Guidelines for Management of Heart Failure. Developed in Collaboration With the American Academy of Family Physicians, American College of Chest Physicians, Heart Rhythm Society, and International Society for Heart and Lung Transplantation 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guidelines for the Management of Heart Failure ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation;2017:135 (24) Classification of Recommendations & Levels of Evidence 3
4 Treatment of HF Stages A to D Stage A At high risk for HF but without structural heart disease or symptoms or HF NYHA Functional Classification None Circle of Life (and Death) of HF Cardiac Output Post MI, heart disease, tobacco use, etc. Afterload Vasoconstriction Systemic vascular resistance Goals of Therapy Improve the patients quality of life by reducing symptoms Prolong survival Alter the natural course of the disease Reduce hospital and emergency department admissions 4
5 Stage A Hypertension and lipid disorders should be controlled in accordance with contemporary guidelines to lower the risk of heart failure. Class I, Level A Other conditions that may lead to or contribute to HF, such as obesity, diabetes mellitus, tobacco use and known cardiotoxic agents, should be controlled or avoided. Class I, Level C Treatment of HF Stages A to D Stage B Structural heart disease but without signs or symptoms of HF. NYHA Functional Classification I No limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF. Recommendations for Prevention & Treatment of Stage B HF COR=Class (strength) of Recommendation; LOE Level of Evidence 5
6 Role of Endogenous Angiotensin II Renin/Aldosterone/Angiotensin System (RAAS) Renal Perfusion Renin Vasodilatory Prostaglandins Histamine Angiotensinogen Angiotensinogen 1 Bradykinin Angiotensin Converting Enzyme (ACE) Angiotensin II Inactive Kinins Angiotensin II Receptor potent peripheral vasoconstriction Afterload and Heart Failure Afterload and Heart Failure 6
7 Treatment of HF Stages A to D Stage C Structural heart disease with prior or current symptoms of HF. NYHA Functional Classification I No limitations of physician activity, ordinary physical activity does not cause symptoms II Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms. III Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms Pharmacological Therapy for Management of Stage C HFrEF HFrED= HF with reduced Ejection Fraction GDMT= Goal Directed Medication Therapy Diuretics Drug Initial Daily Dose(s) Maximum Doses(s) Mean Doses Achieved in Clinical Trials Thiazide Diuretics Hydrochlorothiazide (HCTZ) 25mg twice 100mg daily ** Thiazide-like Diuretics Metolazone (Zaroxolyn ) 2.5mg twice 20mg ** Loop Diuretics Furosemide (Lasix ) 20mg-40mg daily 600mg Sliding scale Bumetanide (Bumex ) 0.5mg 1mg 10mg Sliding scale Indapamide (Lozol ) 2.5mg 5mg COR=I ; LOE = 3 Reduce pre load and after load on the heart by decreasing total blood volume Some benefits to combination therapy (thiazide + loop) Primary side effect: electrolyte imbalance HYPOKALEMIA, hypomagnesemia, hypochloremia, azotemia ( BUN) Might be ameliorated by use with ACEI, ARB, K + sparing diuretic 7
8 Drugs Commonly Used for HFrEF Stage C HF with reduced Ejection Fraction Role of Endogenous Angiotensin II Renin/Aldosterone/Angiotensin System (RAAS) Renal Perfusion Renin Vasodilatory Prostaglandins Histamine Angiotensinogen Angiotensinogen 1 Bradykinin Angiotensin Converting Enzyme (ACE) Angiotensin II Inactive Kinins Angiotensin II Receptor potent peripheral vasoconstriction Angiotensin Converting Enzyme Inhibitors (ACEI) * pril drugs Peripheral vasodilator Reduce blood pressure REDUCE AFTERLOAD ON HEART Adverse effects Hypotension, dizziness, lightheadedness, syncope Cautious use in renal dysfunction Hyperkalemia, worsen renal function ACEI Cough Inhibition of breakdown of Bradykinin Continued dry, non productive cough Associated with ALL ACEI Angioedema Hives Swelling of face, lips, eyes, soft tissue 8
9 Angiotensin II Receptor Blockers * sartan drugs Reduce the vasoconstrictor effect by blocking the receptor where angiotensin II engages Angiotensin converting enzyme is still active Bradykinin does not build up Very low incidence of cough Very low incidence of angioedena Cautious use in renal dysfunction Hyperkalemia Role of Endogenous Angiotensin II Renin/Aldosterone/Angiotensin System (RAAS) Renal Perfusion Renin Vasodilatory Prostaglandins Histamine Angiotensinogen Angiotensinogen 1 Bradykinin Angiotensin Converting Enzyme (ACE) Angiotensin II Inactive Kinins ARB Angiotensin II Receptor potent peripheral vasoconstriction Renin Aldosterone System Mineralocorticoid receptor blocker/aldosterone Antagonists Indicated in more advanced NYHA class III and IV, LVEF 35% and less Aldosterone stimulates the retention of salt (and therefore water), causes myocardial hypertrophy and potassium excretion. In HF there is increased levels of aldosterone due to: Stimulation by angiotensin II Decreased clearance due to liver congestion Spironolactone and eplerenone counter act these effects Also may decrease collagen synthesis that promotes organ fibrosis 30% reduction in mortality in patients on ACEI 9
10 Renin Aldosterone System Mineralocorticoid receptor blocker/aldosterone Antagonists Creatinine should be <2.5 mg/dl in men or <2.0 mg/dl in women (estimated GFR of > 30ml/min/1.73m 2 )before starting therapy. Serum potassium should be < 5 meq/l before starting therapy Adverse effects Hyperkalemia (Once referred to as Potassium Sparing Diuretics ) Gynecomastia and breast pain in men (10%), leading to a high discontinuation rate. Rate no difference than placebo with eplerenone Role of Endogenous Angiotensin II Renin/Aldosterone/Angiotensin System (RAAS) Renal Perfusion Renin Vasodilatory Prostaglandins Histamine Angiotensinogen Angiotensinogen 1 Bradykinin Angiotensin Converting Enzyme (ACE) Angiotensin II Inactive Kinins ARB Angiotensin II Receptor potent peripheral vasoconstriction Pharmacological Therapy for Management of Stage C HFrEF (cont.) 10
11 Drugs Commonly Used for HFrEF Stage C Heart Failure (cont.) Beta Blockers * olol drugs Once considered contraindicated, or at least counterintuitive, in HF At higher doses decreased cardiac output, decreased EF, through adrenergic blockade (blocking epinephrine/adrenalin effect). Reversal of epinephrine mediated reduction in left ventricular compliance. Ventricular relaxation, increased stroke volume and increased glucose utilization. Reduced oxygen consumption Attenuation of the direct toxic effects on heart fiber (lactic acid) Reduces the myocardium remodeling that occurs over time Increased intracellular calcium in damaged heart fibers Normalizes beta receptors in myocardial tissue Beta Blockers (cont.) Careful use (not necessarily contraindicated) in bronchospastic disease (asthma) and diabetes Start doses low and increase carefully Do not stop therapy abruptly. 11
12 Hydralazine + Long Acting Isosorbide First drugs proven to decrease morbidity and mortality in HF Use of potent peripheral vasodilators to reduce afterload on the heart. Addition to ACEI and beta blocker therapy in African Americans. Alternative in patients that are TRULY intolerant to ACEIs and ARBs Adverse Effects Primarily hypotension, dizziness Headaches Drugs Commonly Used for HFrEF Stage C Heart Failure (cont.) Drugs Commonly Used for HFrEF Stage C Heart Failure (cont.) 12
13 Medical Therapy for Stage C HFrEF: Magnitude of Benefit Demonstrated in Randomized Controlled Trials Treatment of HF Stages A to D Stage D Refractory HF requiring specialized interventions NYHA Functional Classification I Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest. New Agent 13
14 Neprilysin Inhibitors Natriuretic Peptide System Counter regulates the detrimental effects of the renin/aldosterone/angiotensin system (RAAS). Has a positive effect on the autonomic (epinephrine) system in HF Reduces sodium and water retention and vasoconstriction that results from the activation of RAAS B type natriuretic peptides (BNP) Promotes natriuresis and vasodilation Past efforts to improve outcomes in HF by infusing recombinant human BNP (Nesiritide ) showed initial promise but failed to improve symptoms and decrease hospital stays. Pathways blocked by ACE inhibitors, angiotensin receptor blockers and neprilysin inhibitors. Pardeep S Jhund, and John J V McMurray Heart doi: /heartjnl Copyright BMJ Publishing Group Ltd & British Cardiovascular Society. All rights reserved. Sacubitril/Valsartan (Entresto ) Sacubitril inhibits neprilysin Increasing endogenous BNP and CMP Inhibiting the RAAS Peripheral vasodilation Valsartan blocks the Angiotensin II receptor PARADIGM HF Trial (McMurray JV, et.al. NEJM 371;11: ) Double blind, comparative trial Sacubitril/valsartan 200mg BID vs. enalapril 20mg BID Sacubitril 97mg + valsartan 103mg = 200mg Primary outcome composite of cardiovascular death or hospitalization for HF. Trial was designed to detect mortality. 14
15 Sacubitril/Valsartan (Entresto ) Results of PARADIGM HF Trial Trial stopped early 27 months because of overwhelming benefit Primary outcome (dealth+hospitalization) Sacubitril/valsartan 21.8% versus 26.5% in the enalapril arm (P<0.001) Cardiovascular death Sacubitril/valsartan 17.0% versus 19.8% in the enalapril arm (P<0.001) Risk of hospitalization Sacubitril/valsartan had a 21.0% lower risk of hospitalization versus enalapril (P<0.001) Controversy around the dose maximum dose of valsartan vs. low dose of enalpril No medication run in period eliminated 20% of the applicants. Were the worst (and most applicable) patients eliminated from the trial? Early termination of what was designed to be a long term trial. Sacubitril/Valsartan (Entresto ) Dosing Sacubitril/valsartan, a neprilysin inhibitor and angiotensin II receptor blocker is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure patients NYHA Class II IV. Initiate therapy sacubitril 49mg/valsartan 50mg (100mg) BID Double the dose after 2 4 weeks, sacubitril 97mg/valsartan 103mg (200mg) Reduced starting dose to sacubitril 24mg/valsartan 26mg (50mg) In patients not taking or taking a low dose of an ACEI or ARB Patients with severe renal failure Patients with moderate liver failure Double the dose to maximally tolerated. Contraindications History of angioedema with ACEI or ARB Hospital Discharge (Reducing Hospital Readmission) 15
16 Hospital Discharge (Reducing Hospital Readmission) Heart Failure Society of America Recommended Elements of HF Disease Management Programs Comprehensive education and counseling individualized to the patient and patient s caregiver Promotion of self care behaviors including potentially selftitration of diuretic dosing (with family member/healthcare provider assistance). Emphasis on behavioral strategies to ensure adequate adherence to instructions Adequate follow up after hospital discharge or clinical instability (preferably within the first 7 days after event) Optimization of oral therapy, especially evidence based therapy Adequate access to healthcare providers Early attention to signs and symptoms of fluid overload and instructions on how to react Assistance with financial and social concerns QUESTIONS? 16
1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More informationARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists
Entresto: An Overview for Pharmacists David Comshaw, PharmD Candidate 2019 1 Gyen Musgrave, PharmD Candidate 2019 1 Suzanne Surowiec, PharmD, BCACP 1 Jason Guy, PharmD 1 1 University of Findlay College
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationContemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium
Contemporary Management of Heart Failure Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Disclosures I have no relevant relationships with commercial
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationDisclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018
Disclosure Statement Heart Failure: Refreshers and Updates Tracy K. Pettinger, PharmD Clinical Associate Professor College of Pharmacy The planners and presenter of this presentation have disclosed no
More informationENTRESTO (sacubitril and valsartan) oral tablet
ENTRESTO (sacubitril and valsartan) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationREVIEW ARTICLE. Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2
Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2 1 University of Missouri School of Medicine, Columbia, MO 2 Division of Cardiovascular Medicine, Department
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationThe Failing Heart in Primary Care
The Failing Heart in Primary Care Hamid Ikram How fares the Heart Failure Epidemic? 4357 patients, 57% women, mean age 74 years HFSA 2010 Practice Guideline (3.1) Heart Failure Prevention A careful and
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationCLINICAL PRACTICE GUIDELINE
CLINICAL PRACTICE GUIDELINE Procedure: Congestive Heart Failure Guideline Review Cycle: Biennial Reviewed By: Amish Purohit, MD, MHA, CPE, FACHE Review Date: November 2014 Committee Approval Date: 11/12/2014
More informationSatish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care
Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 3/2/2014
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center March 2014 Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationHeart Failure CTSHP Fall Seminar
Heart Failure CTSHP Fall Seminar Laurajo Ryan, PharmD, MSc, BCPS, CDE Pharmacist Learning Objectives Outline the pathophysiology of heart failure List triggers for decompensated heart failure Describe
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationCardiovascular Pharmacotherapy
Cardiovascular Pharmacotherapy Overview Mechanism of cardiovascular drugs Indications and clinical use in cardiology Renin-Angiotensin Inhibitors: Angiotensin-Converting Enzyme Inhibitors, Angiotensin
More informationTowards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:
Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Cardiac Output (CO) CO=SVxHR (stroke volume x heart rate) Cardiac output: The amount of blood
More informationHEART FAILURE KEEPING YOUR PATIENT AT HOME
HEART FAILURE KEEPING YOUR PATIENT AT HOME SUZANNE FRAZIER MS, CRNP, NP-C, CHFN HEART FAILURE DISEASE MANAGEMENT COORDINATOR PENN STATE HERSHEY HEART & VASCULAR INSTITUTE IMPACT OF HEART FAILURE In 2010,
More informationUpdate in Congestive Hear Failure DRAGOS VESBIANU MD
Update in Congestive Hear Failure DRAGOS VESBIANU MD Case 58 yo AAM c/o shortness of breath for 3 weeks. Used to walk one mile per day and now he has noticed that he gets short of breath after 2 blocks.
More informationHeart Failure Management Policy and Procedure Phase 1
1301 Punchbowl Street, Harkness Suite 225 Honolulu, Hawaii 96813 Phone (808) 691-7220 Fax: (808) 691-4099 www.queenscipn.org Policy and Procedure Phase 1 Policy Number: Effective Date: Revised: Approved
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More information2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017
Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Julio A. Barcena, M.D. South Miami Heart Specialists Disclosures I have no relevant commercial relationships to
More informationHEART FAILURE-UPDATES AND PRACTICAL APPROACHES TO PATIENT CARE
HEART FAILURE-UPDATES AND PRACTICAL APPROACHES TO PATIENT CARE DR DEAN T. GOROSKI, BCPS, CAPT, USPHS 2018 MPA WINTER CE AND SKI MEETING BIG SKY, MT JANUARY 6, 2018 DISCLOSURE Dr. Goroski has no actual,
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationHeart Failure Treatments
Heart Failure Treatments Past & Present www.philippelefevre.com Background Background Chronic heart failure Drugs Mechanical Electrical Background Chronic heart failure Drugs Mechanical Electrical Sudden
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION SACUBITRIL/VALSARTAN (Entresto Novartis Pharmaceuticals) Indication: Heart Failure With Reduced Ejection Fraction Recommendation: The Canadian
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationPatient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton
Rationale for Initiation, Continuation and Discontinuation (RICaD) Sacubitril/Valsartan (Entresto) For the treatment of symptomatic heart failure with reduced ejection fraction (NICE TA388) This document
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationAdvanced Care for Decompensated Heart Failure
Advanced Care for Decompensated Heart Failure Sara Kalantari MD Assistant Professor of Medicine, University of Chicago Advanced Heart Failure, Mechanical Circulatory Support and Cardiac Transplantation
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationBalanced information for better care. Heart failure: Managing risk and improving patient outcomes
Balanced information for better care Heart failure: Managing risk and improving patient outcomes Heart failure increases hospitalization Heart failure is the most common medical reason for hospitalization
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationReview Article. Pharmacotherapy of Heart Failure with Reduced LVEF. Sachin Mukhedkar, Ajit Bhagwat
Review Article Vidarbha Journal of Internal Medicine Volume 22 January 2017 Pharmacotherapy of Heart Failure with Reduced LVEF 1 2 Sachin Mukhedkar, Ajit Bhagwat ABSTRACT Heart failure with reduced ejection
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 2/20/2017. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading DRG among
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationLCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO. Dario Leosco Università di Napoli Federico II
LCZ696: LA NUOVA RIVOLUZIONE NELLA TERAPIA DELLO SCOMPENSO CARDIACO Dario Leosco Università di Napoli Federico II Projected changes in cardiovascular diseases CVD Deaths Increase 33% CVD DALYS 22% CAD
More informationDisclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationBeta 1 Beta blockers A - Propranolol,
Pharma Lecture 3 Beta blockers that we are most interested in are the ones that target Beta 1 receptors. Beta blockers A - Propranolol, it s a non-selective competitive antagonist of beta 1 and beta 2
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More informationHEART FAILURE. Heart Failure in the US. Heart Failure (HF) 10/5/2015. Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center
HEART FAILURE Martina Frost, PA-C Desert Cardiology of Tucson Northwest Medical Center Heart Failure in the US Prevalence - ~5 million 650,000 new cases annually 300,000 deaths annually Leading DRG among
More informationA new class of drugs for systolic heart failure: The PARADIGM-HF study
INTERPRETING KEY TRIALS CME CREDIT EDUCATIONAL OBJECTIVE: Readers will describe the mechanism and use of angiotensin receptor-neprilysin inhibitors in heart failure MARWA A. SABE, MD, MPH Department of
More informationEvaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%
Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF
More informationBiomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed
Biomarkers in the Age of Sacubitril/Valsa rten: Has the PARADIGM Changed Alan S. Maisel MD FACC Professor of Medicine, University of California, San Diego, Director, CCU and Heart Failure Program San Diego
More informationPosition Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE
Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Over 8,000 patients have been studied in two well-designed placebo-controlled outcome-driven clinical trials to evaluate the
More informationDrugs Used in Heart Failure. Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia
Drugs Used in Heart Failure Assistant Prof. Dr. Najlaa Saadi PhD pharmacology Faculty of Pharmacy University of Philadelphia Heart Failure Heart failure (HF), occurs when cardiac output is inadequate to
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More information